메뉴 건너뛰기




Volumn 26, Issue 4, 2013, Pages 629-635

Management of hyperglycemia in patients with chronic kidney disease

Author keywords

Chronic kidney disease; Diabetes mellitus; Treatment

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE;

EID: 84880095929     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000248     Document Type: Review
Times cited : (10)

References (49)
  • 1
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial Research Group
    • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
    • (1993) N Engl J Med , vol.329 , Issue.14 , pp. 977-986
  • 2
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
  • 3
    • 0029147687 scopus 로고
    • Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
    • Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
    • (1995) Diabetes Res Clin Pract , vol.28 , Issue.2 , pp. 103-117
    • Ohkubo, Y.1    Kishikawa, H.2    Araki, E.3
  • 4
    • 0033055724 scopus 로고    scopus 로고
    • Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
    • Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617-622.
    • (1999) Lancet , vol.353 , Issue.9153 , pp. 617-622
    • Gaede, P.1    Vedel, P.2    Parving, H.-H.3    Pedersen, O.4
  • 5
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • ADVANCE Collaborative Group
    • Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2560-2572
    • Patel, A.1    Macmahon, S.2    Chalmers, J.3
  • 8
    • 0031015510 scopus 로고    scopus 로고
    • Principles of drug administration in renal insufficiency
    • Lam YW, Banerjis S, Atfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharm. 1997;32(1):30-57.
    • (1997) Clin Pharm , vol.32 , Issue.1 , pp. 30-57
    • Lam, Y.W.1    Banerjis, S.2    Atfield, C.3
  • 9
    • 58449085258 scopus 로고    scopus 로고
    • Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
    • Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant. 2009;24(2):338-341.
    • (2009) Nephrol Dial Transplant , vol.24 , Issue.2 , pp. 338-341
    • Haneda, M.1    Morikawa, A.2
  • 10
    • 84880103028 scopus 로고    scopus 로고
    • Evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care
    • The American Diabetes Association's (ADA)
    • The American Diabetes Association's (ADA) Evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care. 2012; 35(Suppl 1):13-57.
    • (2012) Diabetes Care , vol.35 , Issue.SUPPL. 1 , pp. 13-57
  • 11
    • 0005502850 scopus 로고    scopus 로고
    • The use of glycosylated hemoglobin in dialysis patients
    • Tzamaloukas AH. The use of glycosylated hemoglobin in dialysis patients. Semin Dial. 1998;11(3):141-143.
    • (1998) Semin Dial , vol.11 , Issue.3 , pp. 141-143
    • Tzamaloukas, A.H.1
  • 12
    • 34547486527 scopus 로고    scopus 로고
    • Diabetes management issues for patients with chronic kidney disease
    • Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25(3): 90-97.
    • (2007) Clin Diabetes , vol.25 , Issue.3 , pp. 90-97
    • Cavanaugh, K.L.1
  • 13
    • 77951621021 scopus 로고    scopus 로고
    • Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis
    • Alberta Kidney Disease Network
    • Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010;55(5):875-884.
    • (2010) Am J Kidney Dis , vol.55 , Issue.5 , pp. 875-884
    • Shurraw, S.1    Majumdar, S.R.2    Thadhani, R.3    Wiebe, N.4    Tonelli, M.5
  • 14
    • 0033631547 scopus 로고    scopus 로고
    • Impact of end-stage renal disease and dialysis on glycemic control
    • Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13(1):4-8.
    • (2000) Semin Dial , vol.13 , Issue.1 , pp. 4-8
    • Mak, R.H.1
  • 15
    • 0018140320 scopus 로고
    • Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin
    • DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest. 1978;62(2):425-435.
    • (1978) J Clin Invest , vol.62 , Issue.2 , pp. 425-435
    • Defronzo, R.A.1    Tobin, J.D.2    Rowe, J.W.3    Andres, R.4
  • 16
    • 0028028957 scopus 로고
    • Abnormal leucine-induced insulin secretion in chronic renal failure
    • Oh HY, Fadda GZ, Smogorzewski M, Liou HH, Massry SG. Abnormal leucine-induced insulin secretion in chronic renal failure. Am J Physiol. 1994;267(5 Pt 2):F853-F860.
    • (1994) Am J Physiol , vol.267 , Issue.5 PART. 2
    • Oh, H.Y.1    Fadda, G.Z.2    Smogorzewski, M.3    Liou, H.H.4    Massry, S.G.5
  • 18
    • 0026771083 scopus 로고
    • Glucose and insulin metabolism in uremia
    • Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron. 1992;61(4):377-382.
    • (1992) Nephron , vol.61 , Issue.4 , pp. 377-382
    • Mak, R.H.1    Defronzo, R.A.2
  • 19
    • 0026523822 scopus 로고
    • Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients
    • Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992;41(4):1049-1054.
    • (1992) Kidney Int , vol.41 , Issue.4 , pp. 1049-1054
    • Mak, R.H.1
  • 20
    • 35348917135 scopus 로고    scopus 로고
    • Management of glycemia in patients with diabetes mellitus and CKD
    • Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865-879.
    • (2007) Am J Kidney Dis , vol.50 , Issue.5 , pp. 865-879
    • Lubowsky, N.D.1    Siegel, R.2    Pittas, A.G.3
  • 22
    • 0035349026 scopus 로고    scopus 로고
    • Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients
    • Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24(5):886-890.
    • (2001) Diabetes Care , vol.24 , Issue.5 , pp. 886-890
    • Rave, K.1    Heise, T.2    Pfützner, A.3    Heinemann, L.4    Sawicki, P.T.5
  • 23
    • 0032792964 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus
    • Aisenpreis U, Pfützner A, Giehl M, Keller F, Jehle PM. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 1999;14(Suppl 4):5-6.
    • (1999) Nephrol Dial Transplant , vol.14 , Issue.SUPPL. 4 , pp. 5-6
    • Aisenpreis, U.1    Pfützner, A.2    Giehl, M.3    Keller, F.4    Jehle, P.M.5
  • 24
    • 84870597571 scopus 로고    scopus 로고
    • Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis
    • Toyoda M, Kimura M, Yamamoto N, et al. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 2012
    • (2012) J Nephrol
    • Toyoda, M.1    Kimura, M.2    Yamamoto, N.3
  • 26
    • 0026043119 scopus 로고
    • Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: A review
    • Tzamaloukas AH, Oreopoulos DG. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv Perit Dial. 1991;7(7):81-85.
    • (1991) Adv Perit Dial , vol.7 , Issue.7 , pp. 81-85
    • Tzamaloukas, A.H.1    Oreopoulos, D.G.2
  • 27
    • 0025341533 scopus 로고
    • Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus
    • Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol. 1990;29(6):673-684.
    • (1990) Br J Clin Pharmacol , vol.29 , Issue.6 , pp. 673-684
    • Coppack, S.W.1    Lant, A.F.2    McIntosh, C.S.3    Rodgers, A.V.4
  • 28
    • 0015698165 scopus 로고
    • Pharmacokinetic of glipizide in man: Influence of renal insufficiency
    • Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetic of glipizide in man: influence of renal insufficiency. Diabetologia. 1973;9(S1):331-338.
    • (1973) Diabetologia , vol.9 , Issue.S1 , pp. 331-338
    • Balant, L.1    Zahnd, G.2    Gorgia, A.3    Schwarz, R.4    Fabre, J.5
  • 29
    • 33845760213 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2)(Suppl 2): 12-154.
    • (2007) Am J Kidney Dis , vol.49 , Issue.2 SUPPL. 2 , pp. 12-154
  • 30
    • 0029827893 scopus 로고    scopus 로고
    • Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients
    • Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28(9):434-439.
    • (1996) Horm Metab Res , vol.28 , Issue.9 , pp. 434-439
    • Rosenkranz, B.1
  • 31
    • 0029857682 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment
    • Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617-1624.
    • (1996) Diabetologia , vol.39 , Issue.12 , pp. 1617-1624
    • Rosenkranz, B.1    Profozic, V.2    Metelko, Z.3    Mrzljak, V.4    Lange, C.5    Malerczyk, V.6
  • 32
    • 0035904785 scopus 로고    scopus 로고
    • Insulinotropic meglitinide analogues
    • Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358(9294):1709-1716.
    • (2001) Lancet , vol.358 , Issue.9294 , pp. 1709-1716
    • Dornhorst, A.1
  • 33
    • 0028139101 scopus 로고
    • Re-evaluation of a biguanide, metformin: Mechanism of action and tolerability
    • Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30(3):187-228.
    • (1994) Pharmacol Res , vol.30 , Issue.3 , pp. 187-228
    • Sirtori, C.R.1    Pasik, C.2
  • 34
    • 0032969589 scopus 로고    scopus 로고
    • Incidence of lactic acidosis in metformin users
    • Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925-927.
    • (1999) Diabetes Care , vol.22 , Issue.6 , pp. 925-927
    • Stang, M.1    Wysowski, D.K.2    Butler-Jones, D.3
  • 35
    • 48749096999 scopus 로고    scopus 로고
    • National Institute for Health and Clinical Excellence. NICE, Available at, Accessed May 2013
    • National Institute for Health and Clinical Excellence. NICE 2009. Type 2 Diabetes: The management of type 2 diabetes. NICE clinical guideline 87. Available at: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed May 2013.
    • (2009) Type 2 Diabetes: The Management of Type 2 Diabetes. NICE Clinical Guideline , pp. 87
  • 36
    • 84880089144 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, Available at, Accessed May 2013
    • U.S. Food and Drug Administration. Metformin. 2002. Available at: www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf. Accessed May 2013.
    • (2002) Metformin
  • 37
    • 84876358992 scopus 로고    scopus 로고
    • Metformin in patients with chronic kidney disease: Strengths and weaknesses
    • Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26(1):55-60.
    • (2013) J Nephrol , vol.26 , Issue.1 , pp. 55-60
    • Rocha, A.1    Almeida, M.2    Santos, J.3    Carvalho, A.4
  • 38
    • 33746371464 scopus 로고    scopus 로고
    • Protection of the Kidney by thiazolidinediones: An assessment from bench to bedside
    • Sarafidis PA, Bakris GL. Protection of the Kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70(7):1223-1233.
    • (2006) Kidney Int , vol.70 , Issue.7 , pp. 1223-1233
    • Sarafidis, P.A.1    Bakris, G.L.2
  • 39
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
    • RECORD Study Team
    • Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
    • (2009) Lancet , vol.373 , Issue.9681 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3
  • 40
    • 0037705723 scopus 로고    scopus 로고
    • Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis
    • Manley HJ, Pharm D, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003;2(7):861-865.
    • (2003) Pharmacotherapy , vol.2 , Issue.7 , pp. 861-865
    • Manley, H.J.1    Pharm, D.2    Allcock, N.M.3
  • 41
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
    • (2006) Lancet , vol.368 , Issue.9548 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 42
    • 33645533439 scopus 로고    scopus 로고
    • Exenatide: From Gila monster to the pharmacy
    • Triplitt C, Chiquette E. Exenatide: from Gila monster to the pharmacy. J Am Pharm Assoc (2003). 2006;46(1):44-52.
    • (2006) J Am Pharm Assoc (2003) , vol.46 , Issue.1 , pp. 44-52
    • Triplitt, C.1    Chiquette, E.2
  • 43
    • 34548034895 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics of exenatide
    • Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clinl Pharmacol. 2007;64(3):317-327.
    • (2007) Br J Clinl Pharmacol , vol.64 , Issue.3 , pp. 317-327
    • Linnebjerg, H.1    Kothare, P.A.2    Park, S.3
  • 44
    • 45449105789 scopus 로고    scopus 로고
    • Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
    • Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545-555.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.7 , pp. 545-555
    • Chan, J.C.1    Scott, R.2    Arjona, F.J.C.3
  • 45
    • 79961222810 scopus 로고    scopus 로고
    • Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
    • Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11): 1441-1467.
    • (2011) Drugs , vol.71 , Issue.11 , pp. 1441-1467
    • Baetta, R.1    Corsini, A.2
  • 47
    • 84880107782 scopus 로고    scopus 로고
    • Novartis Pharmaceutical UK Ltd, Available at, Accessed 25 May 2011
    • Novartis Pharmaceutical UK Ltd. Summary of product characteristics 'Galvus 50 mg tablets'. 2011. Available at: www.medicines.org.uk/EMC. Accessed 25 May 2011.
    • (2011) Summary of Product Characteristics 'Galvus 50 Mg Tablets'
  • 48
    • 78650724091 scopus 로고    scopus 로고
    • Incretin-based therapies in complex patients: Practical implications and opportunities for maximizing clinical outcomes: A discussion with Dr. Vivian A. Fonseca
    • Fonseca VA. Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med. 2011;124(Suppl 1):54-61.
    • (2011) Am J Med , vol.124 , Issue.SUPPL. 1 , pp. 54-61
    • Fonseca, V.A.1
  • 49
    • 84858011452 scopus 로고    scopus 로고
    • Pharmacology, efficacyy, and safety of linagliptin for the treatment of type 2 diabetes mellitus
    • Neumiller JJ. Pharmacology, efficacyy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012;46(3):358-367.
    • (2012) Ann Pharmacother , vol.46 , Issue.3 , pp. 358-367
    • Neumiller, J.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.